Lupin’s wholly-owned subsidiary -- Hormosan Pharma GmbH (Hormosan) has launch Luforbec 100/6 (beclometasone 100 µg / formoterol 6 µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.
Luforbec 100µg/6µg pMDI is indicated for adult asthma and COPD treatment, where the use of an inhaled corticosteroid and long-acting beta2-agonist (ICS/LABA) is suitable. With the same active ingredients as Foster 100/6 pMDI and an extra fine formulation, Luforbec offers the same licensed indications and similar device characteristics. Luforbec pMDI provide significant cost savings, priced at - 47% below the fixed reference price on the pharmacy selling price.
With a significant portion of the population (5% of adults and 10% of children) currently undergoing asthma treatment, Luforbec 100/6 pMDI aims to provide comprehensive support to patients and healthcare professionals. This launch reflects Lupin’s unwavering commitment to addressing the critical needs of asthma management in Germany.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
